Compare Stocks

→ top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (From Traders Agency) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVEO AVEO Pharmaceuticals	$15.00	$14.97	$3.06 ▼ $15.00	$521.45M	1	601,442 shs	247,800 shs
CBAY CymaBay Therapeutics	$32.48	$32.38	$7.26 ▼ $32.50	$3.73B	0.32	4.11 million shs	73 shs
IVA Inventiva	$3.29 -0.3%	$3.67	$2.22 ▼ $5.05	$172.66M	0.91	35,499 shs	2,824 shs
PEPG PepGen	$11.61 +1.9%	$13.74	$3.72 ▼ $17.51	$375.63M	1.54	116,374 shs	2,214 shs
XOMA XOMA	$26.30 +1.9%	$24.56	$13.48 ▼ $27.00	$306.13M	0.58	21,109 shs	8,646 shs

Beginners Guide To Retirement Stocks

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVEO AVEO Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%
CBAY CymaBay Therapeutics	0.00%	0.00%	0.00%	+39.40%	+214.12%
IVA Inventiva	+1.50%	+3.05%	-11.98%	-13.33%	+27.07%
PEPG PepGen	+8.12%	-6.87%	-23.61%	+65.55%	-9.24%
XOMA XOMA	+1.33%	+6.08%	+4.11%	+30.73%	+38.97%

[Shocking] Elon Musk’s Plan To End Banks (Ad)

Leaked Elon Musk call reveals shocking plan to replace banks. As Musk's plan rolls out, industry experts predict it could spark a wave of mass crypto adoption. Triggering a new crypto bull run. While helping drive a booming crypto asset class up from $2.5-billion to $16-trillion (a 6,400x increase) by 2030.

Click here now to get your copy.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AVEO AVEO Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CBAY CymaBay Therapeutics	0.94 of 5 stars	2.0	0.0	0.0	4.7	0.0	2.5	0.6
IVA Inventiva	2.6245 of 5 stars	3.5	5.0	0.0	0.0	2.6	1.7	0.0
PEPG PepGen	1.7489 of 5 stars	3.5	3.0	0.0	0.0	0.0	2.5	0.6
XOMA XOMA	3.6186 of 5 stars	3.5	2.0	0.0	3.0	2.4	1.7	0.6

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AVEO AVEO Pharmaceuticals	N/A	N/A	N/A	N/A
CBAY CymaBay Therapeutics	2.08	Hold	$28.65	-11.79% Downside
IVA Inventiva	3.00	Buy	$17.00	416.72% Upside
PEPG PepGen	3.00	Buy	$24.67	112.46% Upside
XOMA XOMA	3.00	Buy	$74.00	181.37% Upside

Current Analyst Ratings

Latest CBAY, IVA, AVEO, XOMA, and PEPG Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/8/2024	IVA Inventiva	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$12.00 ➝ $20.00
4/1/2024	IVA Inventiva	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$22.00
3/20/2024	IVA Inventiva	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$22.00
3/7/2024	PEPG PepGen	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$21.00 ➝ $20.00
2/29/2024	CBAY CymaBay Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$32.50
2/20/2024	CBAY CymaBay Therapeutics	SVB Leerink Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform	$32.50
2/16/2024	IVA Inventiva	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$27.00 ➝ $25.00
2/16/2024	XOMA XOMA	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$74.00
2/14/2024	CBAY CymaBay Therapeutics	Lifesci Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform
2/14/2024	CBAY CymaBay Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Neutral	$33.00 ➝ $32.50
2/14/2024	CBAY CymaBay Therapeutics	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral	$25.00 ➝ $32.50

(Data available from 4/23/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AVEO AVEO Pharmaceuticals	$42.29M	12.33	N/A	N/A	$1.33 per share	11.28
CBAY CymaBay Therapeutics	$31.07M	119.92	N/A	N/A	$2.58 per share	12.59
IVA Inventiva	$18.91M	9.13	N/A	N/A	($0.67) per share	-4.91
PEPG PepGen	N/A	N/A	N/A	N/A	$4.55 per share	N/A
XOMA XOMA	$4.76M	64.31	N/A	N/A	$7.72 per share	3.41

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AVEO AVEO Pharmaceuticals	-$53.34M	-$0.84	N/A	28.85	N/A	-30.79%	-81.66%	-28.83%	N/A
CBAY CymaBay Therapeutics	-$105.37M	-$0.97	N/A	N/A	N/A	N/A	-50.72%	-31.04%	5/20/2024 (Estimated)
IVA Inventiva	-$119.51M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A
PEPG PepGen	-$78.63M	-$3.31	N/A	N/A	N/A	N/A	-57.56%	-45.55%	5/9/2024 (Estimated)
XOMA XOMA	-$40.83M	-$4.04	N/A	N/A	N/A	-886.91%	-25.17%	-17.08%	5/14/2024 (Estimated)

Latest CBAY, IVA, AVEO, XOMA, and PEPG Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
3/8/2024	Q4 2023	XOMA XOMA	-$0.36	-$0.49	-$0.13	$0.89	$1.01 million	$1.83 million
3/6/2024	Q4 2023	PEPG PepGen	-$1.01	-$0.82	+$0.19	-$0.82	N/A	N/A
2/28/2024	Q4 2023	CBAY CymaBay Therapeutics	-$0.31	-$0.35	-$0.04	-$0.35	$0.42 million	$0.06 million

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AVEO AVEO Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
CBAY CymaBay Therapeutics	N/A	N/A	N/A	N/A	N/A
IVA Inventiva	N/A	N/A	N/A	N/A	N/A
PEPG PepGen	N/A	N/A	N/A	N/A	N/A
XOMA XOMA	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AVEO AVEO Pharmaceuticals	0.94	2.37	2.35
CBAY CymaBay Therapeutics	N/A	10.96	10.96
IVA Inventiva	N/A	0.96	0.95
PEPG PepGen	N/A	6.43	6.43
XOMA XOMA	1.34	8.68	8.68

Ownership

Institutional Ownership

Company	Institutional Ownership
AVEO AVEO Pharmaceuticals	49.95%
CBAY CymaBay Therapeutics	95.03%
IVA Inventiva	19.06%
PEPG PepGen	58.01%
XOMA XOMA	95.92%

Insider Ownership

Company	Insider Ownership
AVEO AVEO Pharmaceuticals	3.29%
CBAY CymaBay Therapeutics	7.00%
IVA Inventiva	32.00%
PEPG PepGen	3.97%
XOMA XOMA	7.20%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
AVEO AVEO Pharmaceuticals	114	34.76 million	33.62 million	Optionable
CBAY CymaBay Therapeutics	101	114.72 million	106.69 million	Optionable
IVA Inventiva	120	52.48 million	35.68 million	Not Optionable
PEPG PepGen	64	32.35 million	31.07 million	Not Optionable
XOMA XOMA	13	11.64 million	10.80 million	Optionable

CBAY, IVA, AVEO, XOMA, and PEPG Headlines

Source	Headline
	XOMA (NASDAQ:XOMA) shareholders have earned a 16% CAGR over the last five years finance.yahoo.com - April 20 at 9:43 AM
	XOMA (NASDAQ:XOMA) Share Price Passes Above Two Hundred Day Moving Average of $19.93 americanbankingnews.com - April 17 at 2:58 AM
	XOMA Co. (NASDAQ:XOMA) Shares Sold by Stonepine Capital Management LLC marketbeat.com - April 9 at 9:43 PM
	XOMA Corporation Announces Closing of Tender Offer globenewswire.com - April 3 at 9:00 AM
	XOMA Declares Quarterly Preferred Stock Dividends globenewswire.com - March 21 at 7:30 AM
	XOMA Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Kinnate Biopharma Inc. globenewswire.com - March 19 at 4:05 PM
	KINNATE BIOPHARMA INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Kinnate Biopharma Inc. - KNTE businesswire.com - March 13 at 11:49 AM
	XOMA Stock Earnings: XOMA Misses EPS, Misses Revenue for Q4 2023 investorplace.com - March 8 at 1:03 PM
	XOMA Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent and Upcoming Events Expected to Drive Shareholder Value finance.yahoo.com - March 8 at 7:51 AM
	XOMA Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent and Upcoming Events Expected to Drive Shareholder Value globenewswire.com - March 8 at 7:30 AM
	XOMA to Present at Upcoming Investor Conferences in March globenewswire.com - February 28 at 7:30 AM
	KINNATE BIOPHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Kinnate Biopharma Inc. - KNTE businesswire.com - February 19 at 11:03 AM
	Compare with Maple Leaf Green World Inc (4HV0) msn.com - February 18 at 12:30 PM
	XOMA to acquire Kinnate Biopharma thepharmaletter.com - February 17 at 10:21 AM
	XOMA Mar 2024 20.000 put finance.yahoo.com - February 17 at 10:21 AM
	XOMA Jun 2024 25.000 call finance.yahoo.com - February 17 at 10:21 AM
	Biotech Royalty Aggregator XOMA To Acquire Small Cancer-Drug Developer Kinnate Biopharma benzinga.com - February 16 at 1:37 PM
	XOMA Agrees to Acquire Kinnate Biopharma marketwatch.com - February 16 at 8:36 AM
	XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value Right finance.yahoo.com - February 16 at 8:36 AM
	XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value Right finance.yahoo.com - February 16 at 8:36 AM
	XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value Right globenewswire.com - February 16 at 8:00 AM
	With 37% ownership, XOMA Corporation (NASDAQ:XOMA) has piqued the interest of institutional investors finance.yahoo.com - January 20 at 2:06 PM
	XOMA To Pay $1 Mln Milestone To LadRx As FDA Accepts Zevra's Arimoclomol NDA For NPC markets.businessinsider.com - January 11 at 10:48 PM
	FDA Acceptance of Zevra's Arimoclomol NDA Filing for Niemann-Pick Disease Type C (NPC) Results in XOMA Making a $1 Million Milestone Payment to LadRx tmcnet.com - January 11 at 5:46 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

3 Value Stocks Too Small For Buffett’s Portfolio
March 28, 2024 12:16 PM
View 3 Value Stocks Too Small For Buffett’s Portfolio
Foot Locker Builds Up Another Head of Steam; Gains Imminent
March 28, 2024 10:58 AM
View Foot Locker Builds Up Another Head of Steam; Gains Imminent
5 Stocks in the Current Bull Market with Upside to Come
April 5, 2024 10:14 AM
View 5 Stocks in the Current Bull Market with Upside to Come
Are Carnival Shares Ready to Set Sail into the $20s
April 2, 2024 8:00 AM
View Are Carnival Shares Ready to Set Sail into the $20s
Is Norwegian Cruise Lines Ready to Catch Up to Royal Caribbean?
April 16, 2024 6:15 AM
View Is Norwegian Cruise Lines Ready to Catch Up to Royal Caribbean?

All Headlines

Company Descriptions

AVEO Pharmaceuticals

NASDAQ:AVEO

AVEO Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the advancement of therapeutics for oncology, and other areas of unmet medical need. Its product candidates include Tivozanib, Ficlatuzmab, AV-203, AV-380 and AV-353. The company was founded by Ronald A. DePinho, Lynda Chin, and Kenneth E. Weg on October 19, 2001 and is headquartered in Cambridge, MA.

CymaBay Therapeutics

NASDAQ:CBAY

CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta for the treatments of primary biliary cholangitis (PBC). The company also develops MBX-2982, a G protein-coupled receptor 119 (GPR119) agonist, in subjects with type 1 diabetes. It has a license agreement with ABW Cyclops SPV LP to support development of seladelpar for the treatment of PBC. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Fremont, California.

Inventiva

NASDAQ:IVA

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company was founded in 2011 and is headquartered in Daix, France.

PepGen

NASDAQ:PEPG

PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients. The company is also developing PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 1 clinical trial for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. PepGen Inc. was founded in 2018 and is based in Boston, Massachusetts.

XOMA

NASDAQ:XOMA

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets. It has a portfolio with various assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial